Tag: emerging markets

London, United Kingdom, July 26, 2025 (GLOBE NEWSWIRE) -- In response to XRP officially surpassing a $200 billion market capitalization, MGPD Finance Limited, doing business as HashJ, today announced the expansion of its mobile-based digital contract platform to further support XRP and Dogecoin-based reward systems. The platform allows everyday users to engage with the fast-growing digital asset economy—now including XRP-linked reward strategies and Dogecoin contract participation—entirely from their smartphones.

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²

KOSICE, Slovakia, July 24, 2025 (GLOBE NEWSWIRE) -- With hype building across the crypto community, Remittix, the low-fee crypto disrupting traditional remittance infrastructures, has announced the beta launch date of its new multi-chain crypto wallet, to cater to Ethereum, Solana, and more.

Oslo, 22 July 2025: Scatec ASA has been awarded preferred bidder status for a total of 846 MW solar (the Kroonstad PV cluster), in the seventh round of the Renewable Energy Independent Power Producer Procurement Programme (REIPPPP) by the Department of Electricity and Energy (DEE) in South Africa. The award follows a re-allocation of MW under the seventh bid window from onshore wind to solar PV. Once operational, the projects will provide clean and reliable energy under 20-year PPAs.

New Taipei City, Taiwan, July 22, 2025 (GLOBE NEWSWIRE) -- Jyong Biotech Ltd. (Nasdaq: MENS) (the “Company”, “Jyong Biotech”), a science-driven biotechnology company based in Taiwan committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU and Asia, announced completion of its Nasdaq IPO ceremony, and that it participated at the world's largest biotechnology exhibition BIO 2025 International Convention, where it engaged with other global pharmaceutical companies.